Impact of therapeutic drug monitoring of voriconazole in a pediatric population

Pediatric Infectious Disease Journal

Volumn 30, Issue 6, 2011, Pages 533-534

  Brüggemann, Roger J M ^a   Van Der Linden, Jan W M ^a,b   Verweij, Paul E ^a,b   Burger, David M ^a   Warris, Adilia ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Inflammation and Immunity ^*  (Netherlands)

Author keywords

pharmacokinetics; therapeutic drug; voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; PREDNISOLONE; VORICONAZOLE;

ADOLESCENT; ARTICLE; CANDIDEMIA; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INFANT; LOADING DRUG DOSE; MYCOSIS; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SCHOOL CHILD;

EID: 79957987682     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318204d227     Document Type: Article

References (10)

1. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166-2172. (Pubitemid 38691615)
2. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53:935-944.
3. Brüggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008;30:403-411.
4. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211. (Pubitemid 351269158)
5. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27-36.
6. EMA. Vfend: summary of product characteristics, 2009. Available at: http:// www.ema.europa.eu/humandocs/Humans/EPAR/vfend/vfend.htm. Accessed June 2009.
7. de Pauw B, Walsh TJ, Donnelly JP, et al. the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease. Clin Infect Dis. 2008;46:1813-1821.
8. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674-683.
9. Brüggemann RJ, Touw DJ, Aarnoutse RE, et al. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother. 2009;53:303-305.
10. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37:728-732. (Pubitemid 37100817)